Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAUDIXIN vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Raudixin (reserpine) is an indole alkaloid that depletes catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral neuronal storage granules by inhibiting vesicular monoamine transporter (VMAT). This leads to prolonged sympathetic blockade and reduced blood pressure.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Essential hypertension
Hypertension
Usual adult dose: 400–1600 mg orally per day in divided doses; maximum 2400 mg/day; for severe agitation: 50–100 mg intramuscularly every 4–6 hours.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Terminal elimination half-life 50-100 hours; clinical context: once-daily dosing achieves steady state in 1-2 weeks.
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Extensively metabolized in the liver via hydrolysis to reserpic acid and methyl reserpate; also undergoes glucuronidation.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Primarily renal (80-90% as unchanged drug), minor biliary/fecal (10-20%).
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
90-95% bound mainly to albumin and alpha-1 acid glycoprotein.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
10-30 L/kg; large Vd indicates extensive tissue distribution, including adipose and brain.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral: 35-50% due to first-pass metabolism; IM: 100%.
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
No dose adjustment necessary for mild-to-moderate renal impairment (GFR ≥30 m L/min); severe renal impairment (GFR <30 m L/min): reduce dose by 25–50% and titrate cautiously.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 30–50%; Child-Pugh Class C: avoid use or use with extreme caution at reduced doses.
Child-Pugh Class B or C: contraindicated; use not recommended.
Children 6–12 years: initial dose 0.2 mg/kg/day orally in divided doses, increase gradually up to 0.4–0.6 mg/kg/day; maximum 1.0 mg/kg/day. Not recommended for children <6 years.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Elderly patients: start at 10–50% of adult dose (e.g., 100–200 mg/day orally), titrate slowly due to increased sensitivity and higher risk of sedation, anticholinergic effects, and orthostatic hypotension.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
None.
None
May cause severe depression, especially in patients with a history of depression.,Use with caution in patients with peptic ulcer disease due to increased gastric acid secretion.,Risk of biliary colic in patients with gallstones.,Avoid use with MAOIs.,May cause withdrawal symptoms (e.g., severe hypertension) upon abrupt discontinuation.
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
History of depression (especially suicidal ideation),Active peptic ulcer,Ulcerative colitis,Electroconvulsive therapy (within 7 days),Hypersensitivity to reserpine,Concomitant use with MAOIs
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid tyramine-rich foods (aged cheese, cured meats, fermented products) due to risk of hypertensive crisis. Grapefruit juice may increase reserpine levels. Take with food to reduce gastric irritation.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
First trimester: Known human teratogen; may cause major congenital malformations (e.g., neural tube defects, cardiovascular anomalies). Second and third trimesters: Associated with neonatal withdrawal syndrome, respiratory depression, hypotonia, and feeding difficulties after prolonged exposure. Avoid use in pregnancy unless no safer alternative exists.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Raudixin (methamphetamine hydrochloride) is contraindicated during breastfeeding due to high secretion into breast milk, potential for infant toxicity (irritability, poor feeding, seizures), and unknown M/P ratio. Discontinue nursing or drug.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
Pregnancy reduces methamphetamine clearance by up to 30% due to increased plasma volume and enhanced hepatic metabolism; however, no established dose adjustment in pregnancy. Monitor for toxicity and consider dose reduction if adverse effects occur. Avoid use due to teratogenicity.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
RAUDIXIN (reserpine) is a rauwolfia alkaloid that depletes catecholamines from central and peripheral nerve endings. It causes significant sedation, increased gastric acid secretion (caution in peptic ulcer disease), and nasal congestion. Use is limited due to risk of depression and extrapyramidal symptoms. Monitor for hypotension, especially orthostatic. Avoid concurrent use with MAOIs and tricyclic antidepressants.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Do not stop taking abruptly; withdrawal can cause severe hypertension.,You may feel drowsy or dizzy; avoid driving until you know how the drug affects you.,Report any symptoms of depression, unusual dreams, or suicidal thoughts immediately.,Avoid alcohol and over-the-counter cold medications containing decongestants.,Rise slowly from sitting or lying to prevent falls due to blood pressure drop.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAUDIXIN vs ALDORIL D30, answered by our medical review team.
RAUDIXIN is a Antihypertensive that works by Raudixin (reserpine) is an indole alkaloid that depletes catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral neuronal storage granules by inhibiting vesicular monoamine transporter (VMAT). This leads to prolonged sympathetic blockade and reduced blood pressure.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAUDIXIN and ALDORIL D30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAUDIXIN is: Usual adult dose: 400–1600 mg orally per day in divided doses; maximum 2400 mg/day; for severe agitation: 50–100 mg intramuscularly every 4–6 hours.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAUDIXIN and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAUDIXIN is classified as Category C. First trimester: Known human teratogen; may cause major congenital malformations (e.g., neural tube defects, cardiovascular anomalies). Second and third trimesters: Associated with. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.